Shanghai Jiatan Pharmatech
Shanghai Jiatan Pharmatech is a China-based biotechnology company that leads 2 cancer trials in OnCo, testing the dual PI3K and mTOR inhibitor WX390 in advanced solid tumours.
Overview
Shanghai Jiatan Pharmatech is a Shanghai-based drug developer. The ClinicalTrials.gov registry lists it as lead sponsor of Chinese trials of WX390, an oral dual PI3K and mTOR inhibitor, in advanced solid tumours and in combination with toripalimab. No company website could be verified, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06117566 (phase 1/2, A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors) and NCT06117540 (phase 2, A Study of WX390 in Patients With Advanced Solid Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +5
- registry trials +30